The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505).
Ryo Kitagawa
No relevant relationships to disclose
Noriyuki Katsumata
No relevant relationships to disclose
Taro Shibata
No relevant relationships to disclose
Toru Nakanishi
No relevant relationships to disclose
Sadako Nishimura
No relevant relationships to disclose
Kimio Ushijima
No relevant relationships to disclose
Masashi Takano
No relevant relationships to disclose
Toyomi Satoh
No relevant relationships to disclose
Hiroyuki Yoshikawa
No relevant relationships to disclose
Toshiharu Kamura
No relevant relationships to disclose